My Cart
You have no items in your shopping cart.
9 items
Creating an account has many benefits:
# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA3436042 | Functional | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | Leishmania mexicana | 13,179 | ALA3433997 | assay format | St Jude Leishmania Screening | |
2. | ALA3436043 | Functional | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | Leishmania mexicana | 13,179 | ALA3433997 | assay format | St Jude Leishmania Screening | |
3. | ALA3436044 | Functional | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | Leishmania mexicana | 13,179 | ALA3433997 | assay format | St Jude Leishmania Screening | |
4. | ALA1054500 | Functional | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | ALA1157539 | organism-based format | GSK Malaria Screening | |
5. | ALA1054501 | Functional | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | ALA1157539 | organism-based format | GSK Malaria Screening | |
6. | ALA1054502 | Functional | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | ALA1157539 | organism-based format | GSK Malaria Screening | |
7. | ALA1054503 | Functional | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | Plasmodium falciparum | 13,467 | ALA1157539 | organism-based format | GSK Malaria Screening | |
8. | ALA1054504 | Functional | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | Homo sapiens | 13,467 | ALA1157539 | cell-based format | GSK Malaria Screening | |
9. | ALA1054505 | Functional | GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested | 13,467 | ALA1157539 | assay format | GSK Malaria Screening |